News

Although more evidence is needed, CNNs could potentially be most effective in diagnosing patients with vitiligo.

Renata Block, MMS, PA-C, interviewed Erica Ramos, PA-C, the founder of RestoraScalp medicated dry shampoo.

“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.

The analysis findings support the potential use of zinc and vitamin D supplementation in managing alopecia areata.

Soligenix recently shared interim results from a 12-month investigator-initiated study of synthetic hypericin.

Disease severity improved from severe to mild after just 6 weeks of twice daily dosage.

Cemiplimab demonstrated a 68% reduction in recurrence risk for high-risk CSCC in the phase 3 C-POST trial, according to Regeneron’s latest findings.

Balancing ethics, aesthetics, and patient expectations is crucial in dermatology to ensure safe, responsible, and ethical care.

A case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, highlighting unique histopathology and complications.

Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.

Shanna Miranti, MPAS, PA-C, discusses the Umary hyaluronic acid tablets that were recalled in fall 2024.

The new partnership will advance the commercialization of small molecule oral STAT6 for patients around the world.

A 25-day BioLab study revealed their protein-rich wound gel outpaces alternatives, setting the stage for clinical trials.

Data augmentation techniques like cropping and blurring allow AI models to overcome limited datasets, improving skin cancer detection rates.

Researchers are advancing inclusive trials through ancestry-specific endpoints, focusing on skin tone variability, melanin's role, and precision drug modeling.

A study found that UK adults living with psoriasis and vitiligo were better able to self-manage the psychological implications of their condition.

In case you missed it, this week we had news about phase 2b enrollment for VYNE’s vitiligo gel, the impact of anti-inflammatory moisturizers for AD, the newly FDA-approved DermiSphere hDRT, and more.

Explore the top headlines of the week including clinical trial updates, FDA announcements, and expert insights.

At the inaugural Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, reviewed complex cases on AD and PsO and the role of PAs and NPs in advancing patient care.

93.4% of patients saw a positive change in the appearance of forehead wrinkles after 8 weeks of use.

Advancements in therapeutic agents demand innovative strategies for safe, localized skin treatments, Mitragotri argues.

Patients saw an average clearance rate of 74.46% after just 1 session of laser therapy.

Rezpegaldesleukin, a novel IL-2 receptor agonist, enters phase 2b evaluation for atopic dermatitis, aiming to advance therapeutic options for this chronic condition.

Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

The recommendations place an emphasis on the utility of ultrasound-guided placement to enhance safety.

A study revealed ruxolitinib cream's rapid, lasting benefits in pediatric eczema without systemic safety concerns over a 52-week trial period.

The 5% dosage showed a 6-fold increase in non-vellus hair count after just 5 weeks.

DFD-29, FDA-approved in 2024, revolutionizes rosacea management by addressing both erythema and inflammatory lesions with a novel extended-release formulation.

A recent systemic review found FRM to be an effective treatment modality on its own for managing facial acne scars.